John J. L. Jacobs
  • Home
  • Nederlands
  • Resume
    • Science
    • Recent Research
    • Cancer immunotherapy
  • COVID-19
    • Herd Immunity Re-Revisted
      • 1 About herd immunity (HIRR).
      • 2 Three failed attempts.(HIRR)
      • 3. Calculate the costs (HIRR).
      • 4. Incomplete immunity (HIRR).
      • 5. What could possibly go wrong? (HIRR)
      • 6. How should we act? (HIRR)
      • 7. In brief. (HIRR)
    • Simple & complex
    • Epidemic Control
      • Epidemic Control Addendum
    • Summary Two years of COVID-19
    • Two years of COVID-19
      • I. Healthcare threat
      • II. Deceptive virus
      • III. Morbid tales
      • IV. Antivirus immunity
      • V. Stop the outbreak
      • VI. Dark and light reflections
      • VII. Looking forward
    • Humanitarian
    • Questions
      • Disease
      • Vaccines
      • Immunity
      • Epidemics
      • Mutation
      • Politics
    • Virus ethics
      • Transparency
      • Strife
      • Beyond Mortality
      • Special immunity
      • Vaccination
      • Prevent contamination
    • Non-sterilizing immunity
    • Immune responses and vaccines
      • Calculation of infection fatality rate
      • Various Immune responses
      • Different vaccines
      • Trials and results
      • Vaccination and next steps
    • Is it wise to vaccinate?
    • Test, trace & isolate.
    • Different tests
    • Avoid contimination
    • No herd immunity
    • A safe and efficient COVID-19 Vaccine
    • The disease and long-term effects
    • Lost at familiar property
    • Corona Dashboard. 2.0
    • How to fight COVID-19
  • ORTEC
    • P4O2 COVID-19
    • Data science leukemia
    • ​Data to improve patient care
    • Clinical decision support
    • U-Prevent
  • Federa
    • Associations of the Federa
  • Hartblik - blogs
  • Home
  • Nederlands
  • Resume
    • Science
    • Recent Research
    • Cancer immunotherapy
  • COVID-19
    • Herd Immunity Re-Revisted
      • 1 About herd immunity (HIRR).
      • 2 Three failed attempts.(HIRR)
      • 3. Calculate the costs (HIRR).
      • 4. Incomplete immunity (HIRR).
      • 5. What could possibly go wrong? (HIRR)
      • 6. How should we act? (HIRR)
      • 7. In brief. (HIRR)
    • Simple & complex
    • Epidemic Control
      • Epidemic Control Addendum
    • Summary Two years of COVID-19
    • Two years of COVID-19
      • I. Healthcare threat
      • II. Deceptive virus
      • III. Morbid tales
      • IV. Antivirus immunity
      • V. Stop the outbreak
      • VI. Dark and light reflections
      • VII. Looking forward
    • Humanitarian
    • Questions
      • Disease
      • Vaccines
      • Immunity
      • Epidemics
      • Mutation
      • Politics
    • Virus ethics
      • Transparency
      • Strife
      • Beyond Mortality
      • Special immunity
      • Vaccination
      • Prevent contamination
    • Non-sterilizing immunity
    • Immune responses and vaccines
      • Calculation of infection fatality rate
      • Various Immune responses
      • Different vaccines
      • Trials and results
      • Vaccination and next steps
    • Is it wise to vaccinate?
    • Test, trace & isolate.
    • Different tests
    • Avoid contimination
    • No herd immunity
    • A safe and efficient COVID-19 Vaccine
    • The disease and long-term effects
    • Lost at familiar property
    • Corona Dashboard. 2.0
    • How to fight COVID-19
  • ORTEC
    • P4O2 COVID-19
    • Data science leukemia
    • ​Data to improve patient care
    • Clinical decision support
    • U-Prevent
  • Federa
    • Associations of the Federa
  • Hartblik - blogs

Data science for better treatment of leukemia.


ORTEC

Jacqueline Cloos of the Amsterdam University Medical Center studies hematological cancers for the development of algorithms that can be implemented in clinical decision support tools to optimize treatment choices. ORTEC offers added value to this mathematical and statistical research with LogiqCare and the Big Data Portal.
Picture
Figure 1. Acute Myeloid Leukemia in Blood

Acute Myeloid Leukemia (AML; Figure 1) accounts for 1-2% of all tumor-related deaths. This form of cancer can occur at all ages, but the incidence of AML rises with age. Survival without treatment is on average about half a year. Treatment of AML consists of multiple cycles of intensive chemotherapies and depending on the risk of relapse also autologous or allogenic stem cell transplantation. For the choice of the latter the relatively high treatment-related mortality (2% to more than 10%) has to be taken into account. AML has considerable heterogeneity in underlying genetics, mechanisms, and patient-related characteristics. The five-year survival varies from 15 to 70% depending on risk-group classification. Patients with different forms of AML need different therapeutic interventions for optimal survival. In conventional medicine, AML was considered a single disease, with limited therapeutic progress (Figure 2).
Picture
Figure 2. In conventional medicine complex data are reduced prior analytics. In personalized medicine, complex data are differentially analyzed in different interventions to optimize therapy for each patient group independently.

Personalized medicine

ORTEC structures complex medical data from various sources, like centralized patient follow-up and experimental laboratory data on various tumor markers and their numbers in time. Patient data from various source databases are transferred to LogiqCare through the Extract-Transform-Load (ETL) process. These patient data are synced anonymously in the Big Data Portal to have structured data ready for Spotfire analysis for mathematical and statistical research on the structured data. Other research groups from Europe and beyond have expressed their interest to cooperate in this data research project. The aim is to develop algorithms that will be implemented for clinical decision support tools to optimize treatment decisions by physicians and patients. ​

Below is a link to a video of a master student math working on this AML project.
John Jacobs, 30th of july 2020
Powered by Create your own unique website with customizable templates.
  • Home
  • Nederlands
  • Resume
    • Science
    • Recent Research
    • Cancer immunotherapy
  • COVID-19
    • Herd Immunity Re-Revisted
      • 1 About herd immunity (HIRR).
      • 2 Three failed attempts.(HIRR)
      • 3. Calculate the costs (HIRR).
      • 4. Incomplete immunity (HIRR).
      • 5. What could possibly go wrong? (HIRR)
      • 6. How should we act? (HIRR)
      • 7. In brief. (HIRR)
    • Simple & complex
    • Epidemic Control
      • Epidemic Control Addendum
    • Summary Two years of COVID-19
    • Two years of COVID-19
      • I. Healthcare threat
      • II. Deceptive virus
      • III. Morbid tales
      • IV. Antivirus immunity
      • V. Stop the outbreak
      • VI. Dark and light reflections
      • VII. Looking forward
    • Humanitarian
    • Questions
      • Disease
      • Vaccines
      • Immunity
      • Epidemics
      • Mutation
      • Politics
    • Virus ethics
      • Transparency
      • Strife
      • Beyond Mortality
      • Special immunity
      • Vaccination
      • Prevent contamination
    • Non-sterilizing immunity
    • Immune responses and vaccines
      • Calculation of infection fatality rate
      • Various Immune responses
      • Different vaccines
      • Trials and results
      • Vaccination and next steps
    • Is it wise to vaccinate?
    • Test, trace & isolate.
    • Different tests
    • Avoid contimination
    • No herd immunity
    • A safe and efficient COVID-19 Vaccine
    • The disease and long-term effects
    • Lost at familiar property
    • Corona Dashboard. 2.0
    • How to fight COVID-19
  • ORTEC
    • P4O2 COVID-19
    • Data science leukemia
    • ​Data to improve patient care
    • Clinical decision support
    • U-Prevent
  • Federa
    • Associations of the Federa
  • Hartblik - blogs